Climb Bio (CLYM) EBITDA (2020 - 2026)
Climb Bio's (CLYM) quarterly EBITDA came in at -$15.2 million in Q1 2026, up 33.92% YoY from -$11.4 million in Q1 2025, and up 21.17% on a QoQ basis from -$19.3 million in Q4 2025.
Climb Bio (CLYM) EBITDA (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of EBITDA data on file, last reported at -$15.2 million in Q1 2026.
- Quarterly EBITDA rose 33.92% year-over-year to -$15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.1 million (up 41.12% YoY) and the FY2025 annual result came in at -$67.9 million, up 17.24% from the prior year.
- EBITDA rose to -$15.2 million in Q1 2026, from -$19.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$3.0 million in Q1 2024 to a low of -$56.4 million in Q2 2024.
- A 5-year average of -$14.7 million and a median of -$11.7 million in 2024 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 87.18% in 2024, down 739.62% in 2024.
- Tracing CLYM's EBITDA over 5 years: stood at -$9.6 million in 2022, then surged by 46.39% to -$5.1 million in 2023, then tumbled by 113.02% to -$10.9 million in 2024, then slumped by 76.85% to -$19.3 million in 2025, then climbed by 21.17% to -$15.2 million in 2026.
- The last three EBITDA figures came in at -$15.2 million (Q1 2026), -$19.3 million (Q4 2025), and -$14.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | -15.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.36 Mn |
| Mar 31, 2026 | -15.21 Mn |
| Dec 31, 2025 | -19.30 Mn |
| Sep 30, 2025 | -14.89 Mn |
| Jun 30, 2025 | -10.68 Mn |
| Mar 31, 2025 | -23.02 Mn |
| Dec 31, 2024 | -10.91 Mn |
| Sep 30, 2024 | -11.73 Mn |
| Jun 30, 2024 | -56.37 Mn |
| Mar 31, 2024 | -3.01 Mn |
| Dec 31, 2023 | -5.12 Mn |
| Sep 30, 2023 | -5.00 Mn |
| Jun 30, 2023 | -6.71 Mn |
| Mar 31, 2023 | -23.44 Mn |
| Dec 31, 2022 | -9.55 Mn |
| Sep 30, 2022 | -8.75 Mn |
| Jun 30, 2022 | -13.70 Mn |
| Mar 31, 2022 | -13.13 Mn |
| Dec 31, 2021 | -10.70 Mn |
| Sep 30, 2021 | -9.38 Mn |